Assembling the evidence…
Limitation: This content is identified as Perspective / Viewpoint. Evaluation of this content might be partial, and should be treated as indicative.
Blood-based biomarkers (BBMs) for Alzheimer disease (AD) offer widely expanded access to biomarker-informed diagnoses in community settings that have previously lacked such resources. However, integrating them into current clinical diagnostic practice presents challenges, particularly in the diagnosis of mild cognitive impairment (MCI). Limited data are available to guide clinicians on when to test, how to counsel patients with MCI and a positive AD BBM result about their risk of dementia progression, or which evidence-based dementia prevention strategies or treatments to recommend. This Perspective article outlines the key challenges faced by clinicians and patients when addressing a diagnosis of "MCI due to AD" and offers suggestions for appropriate pretest counseling and future research directions to address current knowledge gaps.
Biomarkers, therefore, inform the presence of underlying AD pathology and risk rather than functioning as standalone diagnostic tests.
group-level progression evidence supports the distinction, though narrative source selection limits certainty
the risk of progression to dementia is approximately fivefold higher among those with MCI who are both amyloid-positive and tau-positive compared with those who are biomarker-negative
cited meta-analytic estimate with appropriate subgroup scope, capped because it was singly enumerated
PPV and specificity are likely to be reduced in primary care populations with a lower prevalence of AD pathology
prevalence-sensitive diagnostic performance is appropriately qualified, capped because it was singly enumerated
Derived from the full evaluation — not a separate score.
Strengths
The natural-history section consistently explains that biomarker positivity changes etiologic likelihood and group risk without determining whether or when an individual will develop dementia.
↳ The Natural History and Risk of Progression
The counseling sections consider reassurance, treatment and trial eligibility, planning, anxiety, stigma, medicalization, indeterminate results, and added investigations rather than arguing from only one side.
↳ What Does the Diagnosis Mean?; How to Counsel: Disclosure and Communication
The discussion links primary-care validation, service capacity, reimbursement, cost-effectiveness, and ongoing ADAPT and READ-OUT studies to future guideline and policy decisions.
↳ Future Research Directions and Recommendations
Limitations
The article states that it reviews current evidence but provides no search, inclusion, or source-selection account, limiting confidence in the completeness of broad absence-of-evidence claims.
↳ Introduction, final paragraph; full article
Although the abstract promises suggestions and the introduction mentions practical frameworks, the body mainly offers general principles and calls for future framework development.
↳ Abstract; Introduction; Future Research Directions and Recommendations
The age-related comparison of positive non-progressors with reassured negative cases is uncited, while the proposed 6- or 12-month follow-up interval is more specific than the preceding evidence.
↳ How to Counsel: Disclosure and Communication, final paragraph; Conclusion, final paragraph
The paper’s strongest feature is its consistent separation of biomarker-defined pathology, group-level progression risk, and individual prognostic uncertainty. Its broad engagement with diagnostic frameworks, disclosure effects, service organization, and economics makes the synthesis relevant to clinicians and policymakers. The quality score is held near the boundary between limited and clearly strong work because the stated evidence review has no transparent source-selection method and does not produce the promised practical counseling framework. The proposed follow-up interval and the uncited age-related comparison also require tighter calibration to the evidence presented.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Sound3.5
Confidence mediumThe article organizes diagnostic meaning, prognosis, management, disclosure, and health-system implications around a timely clinical question. Its advance remains a synthesis and research agenda rather than a new counseling framework or resolution of the evidence gap.
“to review current evidence on the diagnosis, prognosis, and management of individuals with MCI due to AD”
The sections form a logical progression from test interpretation through prognosis, management, disclosure, and recommendations, with benefits and harms considered together. No source-identification or selection process is reported despite the stated evidence-review aim.
“The aim of this Perspective article was to review current evidence”
The article repeatedly distinguishes group-level risk information from deterministic individual prognosis, making the reasoning easy to follow. The promise of practical counseling frameworks and the specific 6- or 12-month follow-up proposal are more concrete than the supporting content.
“it does not provide information about the timing or even the certainty of clinical progression for an individual”
The discussion engages major US, UK, and international diagnostic frameworks and connects specialist-setting evidence, attrition, primary-care uncertainty, and economic constraints to interpretation. Coverage is broad but narrative rather than transparently systematic.
“Most of these studies take place in specialist tertiary settings.”
Caveats4 of 4 checks
The central argument is coherent, but two recommendations or comparisons are stated more precisely than the supporting discussion permits. These issues are localized and do not overturn the paper’s overall conclusions.
The article is a narrative Perspective without new participant data, images, or statistical analyses requiring ethics approval, registration, or data and code availability. No conduct inconsistency is apparent in the supplied text.
Flags: 0 declared / 5 total
41 references in manuscript 37 of 37 checkable references found in an index 4 are books, websites or datasets — counted, but not index-checkable
No retraction notice found in Retraction Watch.
Sources: Retraction Watch ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
The paper offers counseling principles and proposed pathway elements but no tested intervention, validated counseling framework, or implementation guide. Its practical recommendations therefore remain pre-deployment.
“Future research should prioritize developing and evaluating structured communication and education frameworks”
AI-generated, human-governed. Something look off? Contact us to request a review.